NO20030706L - Substituerte imidazoler som TAFIA inhibitorer - Google Patents

Substituerte imidazoler som TAFIA inhibitorer

Info

Publication number
NO20030706L
NO20030706L NO20030706A NO20030706A NO20030706L NO 20030706 L NO20030706 L NO 20030706L NO 20030706 A NO20030706 A NO 20030706A NO 20030706 A NO20030706 A NO 20030706A NO 20030706 L NO20030706 L NO 20030706L
Authority
NO
Norway
Prior art keywords
substituted imidazoles
tafia inhibitors
tafia
inhibitors
imidazoles
Prior art date
Application number
NO20030706A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030706D0 (no
Inventor
Charlotte Moira Norfo Allerton
Julian Blagg
Mark Edward Bunnage
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020346A external-priority patent/GB0020346D0/en
Priority claimed from GB0027409A external-priority patent/GB0027409D0/en
Priority claimed from GB0029556A external-priority patent/GB0029556D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20030706D0 publication Critical patent/NO20030706D0/no
Publication of NO20030706L publication Critical patent/NO20030706L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
NO20030706A 2000-08-17 2003-02-14 Substituerte imidazoler som TAFIA inhibitorer NO20030706L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0020346A GB0020346D0 (en) 2000-08-17 2000-08-17 Pharmaceuticals
GB0027409A GB0027409D0 (en) 2000-11-09 2000-11-09 Pharmaceuticals
GB0029556A GB0029556D0 (en) 2000-12-04 2000-12-04 Pharmaceuticals
PCT/IB2001/001425 WO2002014285A1 (en) 2000-08-17 2001-08-08 Substituted imidazoles as tafia inhibitors

Publications (2)

Publication Number Publication Date
NO20030706D0 NO20030706D0 (no) 2003-02-14
NO20030706L true NO20030706L (no) 2003-04-15

Family

ID=27255849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030706A NO20030706L (no) 2000-08-17 2003-02-14 Substituerte imidazoler som TAFIA inhibitorer

Country Status (38)

Country Link
EP (1) EP1311488B1 (da)
JP (2) JP4119746B2 (da)
KR (1) KR20030022412A (da)
CN (1) CN1443173A (da)
AP (1) AP1375A (da)
AR (1) AR035580A1 (da)
AT (1) ATE447557T1 (da)
AU (1) AU2001276605A1 (da)
BG (1) BG107330A (da)
BR (1) BR0113289A (da)
CA (1) CA2419633C (da)
CY (1) CY1109693T1 (da)
CZ (1) CZ2003388A3 (da)
DE (1) DE60140368D1 (da)
DK (1) DK1311488T3 (da)
DO (1) DOP2001000233A (da)
EA (1) EA005532B1 (da)
EE (1) EE200300070A (da)
ES (1) ES2334101T3 (da)
HR (1) HRP20030103A2 (da)
HU (1) HUP0303763A3 (da)
IL (1) IL153225A0 (da)
IS (1) IS6638A (da)
MA (1) MA26940A1 (da)
MX (1) MXPA03001425A (da)
NO (1) NO20030706L (da)
NZ (1) NZ522823A (da)
OA (1) OA12362A (da)
PA (1) PA8525401A1 (da)
PE (1) PE20020352A1 (da)
PL (1) PL361054A1 (da)
PT (1) PT1311488E (da)
SI (1) SI1311488T1 (da)
SK (1) SK1732003A3 (da)
SV (1) SV2002000602A (da)
TN (1) TNSN01126A1 (da)
UY (1) UY26889A1 (da)
WO (1) WO2002014285A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
EP1467731A1 (en) * 2002-01-22 2004-10-20 Pfizer Limited 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
JP2005516972A (ja) * 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのtafi−a阻害剤として使用される3−(イミダゾリル)−2−アミノプロピオン酸
US8512675B2 (en) 2003-04-29 2013-08-20 Mallinckrodt Llc N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
ZA200603165B (en) * 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (ja) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心筋の再灌流の増強およびpciの容易化のためのtafi阻害剤の使用
DE102005049385A1 (de) * 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
NZ577312A (en) * 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
EP2361910A4 (en) * 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd CONNECTION WITH TAFIA-INHIBITOR EFFECT
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
LT2548871T (lt) * 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cikloalkilpakeistieji imidazolo dariniai
CN102884053B (zh) 2010-03-18 2016-03-02 第一三共株式会社 环丙烷甲酸衍生物
PE20141161A1 (es) * 2011-05-17 2014-10-01 Pharmasyntez Los compuestos para el tratamiento y la prevencion de la adhesion, las composiciones farmaceuticas relacionados con el compuesto y los metodos para la prevencion y el tratamiento de adherencias
DK2734508T3 (da) * 2011-07-22 2018-05-22 Cambrex Karlskoga Ab Nye fremgangsmåder til fremstilling af 4-substituerede imidazoler
WO2013039202A1 (ja) * 2011-09-15 2013-03-21 第一三共株式会社 新規アクリル酸誘導体
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
DK3359528T3 (en) 2015-10-07 2022-03-07 Mitobridge Inc Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3437641A4 (en) * 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
KR102430906B1 (ko) * 2016-04-13 2022-08-10 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163661A (ja) * 1984-09-05 1986-04-01 Microbial Chem Res Found ヒスタジン関連化合物
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
CA2419633C (en) 2011-05-10
ES2334101T3 (es) 2010-03-05
TNSN01126A1 (fr) 2005-11-10
AU2001276605A1 (en) 2002-02-25
HRP20030103A2 (en) 2003-04-30
DOP2001000233A (es) 2002-05-15
EA200201239A1 (ru) 2003-08-28
JP4119746B2 (ja) 2008-07-16
PA8525401A1 (es) 2002-04-25
SV2002000602A (es) 2002-10-24
DK1311488T3 (da) 2010-01-04
PE20020352A1 (es) 2002-05-11
JP2004506044A (ja) 2004-02-26
CZ2003388A3 (cs) 2004-03-17
EA005532B1 (ru) 2005-04-28
IS6638A (is) 2002-11-28
WO2002014285A1 (en) 2002-02-21
IL153225A0 (en) 2003-07-06
KR20030022412A (ko) 2003-03-15
ATE447557T1 (de) 2009-11-15
OA12362A (en) 2004-04-07
HUP0303763A2 (hu) 2004-04-28
DE60140368D1 (de) 2009-12-17
EP1311488B1 (en) 2009-11-04
AP1375A (en) 2005-03-03
AR035580A1 (es) 2004-06-16
SK1732003A3 (en) 2004-08-03
JP4778531B2 (ja) 2011-09-21
NZ522823A (en) 2004-11-26
UY26889A1 (es) 2002-03-22
PT1311488E (pt) 2009-12-30
NO20030706D0 (no) 2003-02-14
EP1311488A1 (en) 2003-05-21
MA26940A1 (fr) 2004-12-20
SI1311488T1 (sl) 2010-01-29
AP2001002250A0 (en) 2001-09-30
PL361054A1 (en) 2004-09-20
CN1443173A (zh) 2003-09-17
EE200300070A (et) 2005-02-15
HUP0303763A3 (en) 2004-06-28
CY1109693T1 (el) 2014-08-13
CA2419633A1 (en) 2002-02-21
BR0113289A (pt) 2003-06-17
BG107330A (en) 2003-06-30
MXPA03001425A (es) 2003-06-06
JP2008169224A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
DK1311488T3 (da) Substituerede imidazoler som tafia-inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
NO20014642L (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE524441T1 (de) Vla-4-inhibitoren
NO20030472D0 (no) Imidazolderivater
DE60234125D1 (de) E inhibitoren
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DE60238794D1 (de) Hydantoinderivate als MMP-Inhibitoren
DK1140840T3 (da) omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
ATE360620T1 (de) Imidazolderivate
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20032807L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
NO20043457L (no) 3-(imidazolyl)-2-alkoksypropansyrer som TAFIA inhibitorer
PT1339695E (pt) Inibidores da farnesiltransferase
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application